Join MitoAction and Dr. Jan Smeitink, CEO of Khondrion for our our March Expert Series presentation. MELAS spectrum (m.3243A>G) disorders belong to the most frequently encountered group of primary mitochondrial diseases with an unmet medical need for treatment development. Following an introduction of the clinical disease spectrum Dr. Smeitink will discuss the development and state-of-art of Khondrion’s lead product sonlicromanol.
There was much discussion about current research in FAODs at our recent International Metabolic conference last month. Reneo Pharmaceuticals recently released positive results from...
Dr. Matt Kline & Dr. Guy Miller
Join MitoAction and Acton Pharmacy’s Clinical Pharmacist, Ted Toufas as we revisit and provide the latest updates about the mito cocktail! The mito cocktail...